INDOLYLALKYLAMINES AND p-CARBOLINES
Monoamine oxidase inhibitory activity in vivo (a) Monoamine oxidase activity was measured, as described above, in brain homogenates prepared from mice treated with test compounds. Tissue concentrations of 400 mg wet wt/ml. buffer were used.
(b) The potentiation of tremors produced by 5-hydroxytryptophan in mice pretreated with test compounds was measured by the method described by Lessin (1959) . Results are expressed relative to the activity of a standard inhibitor, such as harmaline.
Estimations of drug levels in brain
Indolylalkylamines were estimated by the methods referred to in an earlier paper (Lessin, Long & Parkes, 1966) ; harmaline was extracted by the method described by Udenfriend et al. (1958) and estimated fluorimetrically by comparison with standards after thin-layer chromatography.
Inhibition of the uptake of 5-hydroxytryptamine
The methods used for ox platelets in vitro, and for rat and mouse platelets in vivo are described in a previous paper (Lessin, Long & Parkes, 1965b) . In addition, some values were obtained on mouse platelets in vitro by the method described by Stacey (1961) using 5-hydroxytryptamine labelled with 14C. For in vivo studies in mice using labelled 5-hydroxytryptamine, blood withdrawn by heart puncture from several mice was pooled, platelets isolated and counted, as in the method quoted above.
The compounds studied were synthesized by Heath-Brown and Philpott. Details concerning some of these have appeared (Heath-Brown & Philpott, 1965) and others are yet to be published.
RESULTS
Activity in producing tremors was assessed in mice treated with the test compound, in doses up to 100 mg/kg, intraperitoneally. Active compounds are placed in Class A of Tables 1 and 2 , in which is found the reference compound, a-methyltryptamine (Ro 3-0926). Compounds causing tremors only in mice pretreated with pargyline (" Latent " stimulation) are placed in Class B of Tables 1 and 2 , in which are found the reference compounds, a,a-dimethyltryptamine (Ro 3-1638) and harmaline. Compounds causing no tremors under these conditions in doses up to 20 mg/kg intraperitoneally are classed as inactive (Class 0). Activities causing tremors after intraperitoneal injection in mice are quoted relative to that of Ro 3-0926, which is active at doses of 10 to 25 mg/kg. Similarly, values for activity in causing tremors in mice repeatedly pretreated with pargyline are also given; in such mice, Ro 3-0926 was active in doses of 0.5 to 1.5 mg/kg.
It will be seen that stimulant activity was frequently found among the substituted indolylalkylamines (Table 1) . Few of the 8-carbolines, however, were stimulant and then only after pargyline pretreatment (Table 2) . It should be mentioned that harmaline and other f8-carbolines do cause a type of tremor after injection in mice. This, however, is a recognizably different, coarser tremor than that caused by indolylalkylamines, or 5-hydroxytryptophan following monoamine oxidase inhibition, and, in particular, is characterized by not occurring in the confined space in which the mice were placed for measurement of tremor.
Inhibition of monoamine oxidase
In vitro Table 1 gives the activities, relative to that of harmaline, of substituted indolylalkylamines, calculated from the concentrations required to cause 50% inhibition. This value for harmaline is 3 x 10-7M. It will be seen that the values vary over approximately a twentyfold range, and show some degree of correlation with stimulant activity. By assigning arbitrary ranking values to the stimulant categories in which the compounds are placed, a significant correlation was found with the in vitro log 150 values (r=0.36; P<0.01 for 39 values). Relative inhibitory activities are given for a number of P-carbolines in Table 2 . Many of these, although possessing only " latent " stimulant activity, showed enzyme inhibitory activities several orders greater than those of the indolylalkylamines.
In vivo  Tables 1 and 2 show the activities of the indolylalkylamines and /-carbolines in causing tremors in mice treated with 5-hydroxytryptophan; harmaline was active at doses of 0.5 to 1.5 mg/kg intraperitoneally.
The 8-carbolines as a group are more active than the indolylalkylamines but the latter show higher relative activities in vivo. Table 3 shows the degree of inhibition of the brain enzyme measured by the disappearance of 5-hydroxytryptamine incubated with brain homogenates prepared from animals treated with inhibitors, expressed as percentage of that disappearing from control homogenates. It also shows the concentrations of each compound which would be required to produce the inhibition observed, if added in vitro. It may be seen that these concentrations agree with the brain levels of compound actually found in animals Inhibition of 5-hydroxytryptamine uptake by blood platelets Activities, relative to tryptamine, of various indolylalkylamines and fl-carbolines in inhibiting 5-hydroxytryptamine uptake by suspensions of ox blood platelets in vitro are shown in Tables 1 and 2 . In these experiments tryptamine caused 50% inhibition at 9.5 x 10-5M. It will be seen that all compounds of both series show a very similar order of activity. The Tables also show that treatment of rats or mice with several indolylalkylamines prevented the blood platelets from taking up as much 5-hydroxytryptamine as those of control animals. Harmaline and other /3-carbolines showed no detectable in vivo reduction of 5-hydroxytryptamine uptake in the largest dose that could be given. On the contrary, they caused a significant increase in uptake (Table 4) . 
DISCUSSION
Two series of compounds, indolylalkylamine derivatives related to a-methyltryptamine and /8-carboline derivatives related to harmaline, have been studied for stimulant properties; as inhibitors of monoamine oxidase; and for interference with uptake of 5-hydroxytryptamine by blood platelets. Stimulant properties were more marked in the indolylalkylamines, while the /3-carbolines were the more powerful inhibitors of monoamine oxidase. The property of inhibiting 5-hydroxytryptamine uptake in vitro was of a similar, moderate order throughout the two series, although the carbolines showed no activity in vivo.
Structure-activity relations
The structures of the indolylalkylamine derivatives, shown in Table 1 The /-carbolines may be considered in three groups differing in the degree of saturation of the pyridine ring. In general, compounds in the dihydro series, to which harmaline belong are more active monamine oxidase inhibitors than corresponding compounds in either the aromatic or the tetrahydro series (compare harmaline, harmine and tetrayhdroharmine; harmalol and harmol) (cf. Udenfriend et at., 1958; Pletscher et at., 1959) ; Ro 3-1620 and Ro 3-1666; Ro 3-1675, Ro 3-1697 and Ro 3-1699. Alkylation of the 7-hydroxy group increases activity over the parent phenol. This effect increases with chain length to a maximum which is reached for monoamine oxidase inhibition with ethyl or propyl (compare the series: harmalol, harmaline, Ro 3-1620, Ro 3-1675, Ro 3-1676, Ro 3-1651, Ro 3-1587 and Ro 3-1590; harmol, harmine, Ro 3-1666, Ro 3-1697 and Ro 3-1699). The alkoxy group is less effective for activity in the 6-position than in the 7-, and 6-alkoxy compounds are inferior to those lacking any substituent in this position. (Compare Ro 3-1594 with harmaline and Ro 3-1564 (harmalan)). Replacement of the 1-methyl group by longer alkyl chains reduces activities. (Compare the series: harmaline, Ro 3-1764, Ro 3-1768 and Ro 3-1774).
Significance of activities
In an earlier paper (Lessin et al., 1965a) it was argued that, whereas inhibition of monoamine oxidase alone could result in the accumulation of tissue amines sufficient to cause central stimulation, this was unlikely to be responsible for the stimulant properties of compounds like a-methyltryptamine, since drugs far more potent as inhibitors of the enzyme lacked these stimulant properties. The distribution of stimulant activities among the substituted indolylalkylamines reported here, and the degree of correlation found with their activities in inhibiting monoamine oxidase, suggest, however, that these two properties are related to some extent, since only the more active inhibitors exert frank stimulation, the less active inhibitors causing stimulation only after prior irreversible enzyme inhibition.
The higher order of monoamine oxidase inhibitory activities found both in vitro and in vivo for the 8-carboline derivatives is clearly not correlated in the same manner with stimulant properties in mice, since none of these compounds is even moderately stimulant except in animals pretreated with an irreversible inhibitor. In attempting to find a reason for this difference between the P-carbolines and the indolylalkylamines, we may consider the other property that was suggested in an earlier paper as contributing to the stimulant actions of the latter class-namely, inhibition of amine uptake. But all the indolylalkylamines show very similar activities in reducing the uptake of 5-hydroxytryptamine by ox platelets in vitro, although they differ in stimulant potency. Moreover, the ,l-carbolines are also active in inhibiting the 5-hydroxytryptamine uptake in vitro, and their activities are of the same order as those of the indolylalkylamines. When activities in vivo are considered, however, the /3-carbolines do not reduce the uptake of 5-hydroxytryptamine. Indeed, they are found to increase the amount taken up, as might be expected, from their inhibition of monoamine oxidase. These results were obtained using blood platelets as a model system and the reservation must be made that the activities found may not reflect those operating in the central nervous system.
We may thus conclude that stimulant activity (tremors) in the indolylalkylamine and /3-carboline derivatives depends both on inhibition of monoamine oxidase and interference with tissue amine distribution. Where both actions are exerted in vivo, as in the indolylalkylamines, the degree of stimulant activity appears to depend on the degree of enzyme inhibitory activity. Where activity in interfering with amine distribution is weak, as in the P-carbolines, even higher activity as enzyme inhibitors does not result in stimulant properties.
Regarding the relative potency of indolylalkylamines and /3-carbolines as inhibitors of monoamine oxidase in vivo, the evidence from brain homogenates suggests that compounds of both series may exert in vivo the same relative activities that are found in vitro. It must be remembered that determination of enzyme inhibition by reversible inhibitors given in vivo suffers from several objections. These result principally from the effects of the destruction of tissue organization, the inevitable dilution and the subsequent addition of substrate upon equilibrium between enzyme and inhibitor. The resulting situation in the homogenate resembles that following addition of inhibitor in vitro. The procedure may, in fact, amount to a method for estimating the quantity of inhibitor present by the inhibition of enzyme observed, and thus the results agree with those of determination by other methods (Table 4) . On the other hand, judged by potentiation of the stimulant effect of 5-hydroxytryptophan, the indolylalkylamines were considerably more active, relative to the P-carbolines, than would appear from their in vitro activities. Although potentiation of 5-hydroxytryptophan tremors has been taken as a measure of monoamine oxidase inhibition (Lessin, 1959) , the assumption that this is the only operative factor may not be true in the case of compounds such as the indolylalkylamines. Their property of interfering with amine distribution could contribute to potentiation of the tremorigenic action of injected 5-hydroxytryptophan by rendering the resultant 5-hydroxytryptamine in the tissues more effective for stimulation. They would thus appear unduly active in comparison with other inhibitors which do not exert such an effect. SUMMARY 1. A number of indolylalkylamine and /3-carboline derivatives have been examined as inhibitors, both in vitro and in vivo, of monoamine oxidase and uptake of 5-hydroxytryptamine by blood platelets, and for activity in causing tremors in mice.
2. Stimulant activity in the indolylalkylamine series showed some correlation with monoamine oxidase inhibitory activity, the less active compounds causing tremors only after treatment of the mice with irreversible inhibitors of the enzyme.
3. Although more potent inhibitors of monoamine oxidase, the f3-carboline derivatives showed no stimulant properties except in mice pretreated with irreversible inhibitors.
4. Similar activities in reducing the uptake of 5-hydroxytryptamine by blood platelets in vitro were found in both groups, but the 8-carbolines did not show this activity in vivo.
5. It is suggested that the property of interfering with amine distribution permits the indolylalkylamine derivatives to exert stimulant activity, the degree of which may depend upon monoamine oxidase inhibitory activity, while the more potent enzyme inhibitors among the 8-carboline derivatives are weaker stimulants because they do not reduce amine uptake in vivo.
6. It is further suggested that interference with amine distribution contributes to an unduly high apparent monoamine oxidase inhibitory activity for the indolylalkylamines, measured in vivo by the potentiation of the stimulant effects of 5-hydroxytryptophan, compared with the activity of f8-carbolines such as harmaline.
